Background and Purpose: Antibiotic resistance rate is increasing in Acinetobacter species, especially in Acinetobacter baumannii, as the most important pathogen of hospital and ICU . This research aimed to evaluate antibiotic resistant rate of Acinetobacter spp. isolated from patients admitted to ICUs in educational hospitals affiliated with Mazandaran University of Medical Sciences.
Introduction
Acinetobacter is a group of ever-evolving opportunist pathogens which affects various groups of people, especially patients hospitalized in ICU (Ramphal & Ambrose, 2006) . This is a non-fermentative, nonmotile, gram-negative bacteria commonly found in water and soil. Acinetobacter lives as normal flora in healthy people's Oropharynx and in recent years have been reported as a major factor in hospital infection (Hanlon, 2005; Ku et al., 2000) . The most important species of this organism is Acinetobacter baumannii which causes different types of infections including respiratory system infection, urinary tract infection, blood and wound infection, particularly in ICU. More over this organism forms biofilms on abiotic surfaces, a phenotype that can enucleate its ability to survive in nosocomial environments and to cause infections with devices in immunocompromised cases (He et al., 2015) . In recent years, different species of Acinetobacter have become even more resistant (Coelho et al., 2004) .
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). Other places of sample isolation included wound sites (n= 5, 10%), blood culture (B/C) and urinary culture (U/C) (n= 3 each, 6%) and cerebrospinal fluid culture (CSF/C), Darren, Bronchoalveolar lavage (BAL) and Tracheostomy (n= 1 each, 2%). Antibiogram results using disc diffusion and E-test method are presented in table 1 and 2, respectively. The patients were followed for 3 to 6 weeks. Death occurred in 31 cases (62%) and 19 patients (38%) recovered. 
Discussion
This study aimed to evaluate the prevalence of antibiotical resistance of Acinetobacter species isolated from 50 patients hospitalized in ICUs of four University affiliated hospitals. Environmental flexibility and extended-spectrum of resistive variable, has made Acinetobactera very dangerous nosocomial pathogen (Nordmann, 2004) . There are many accounts of Multi-drug resistance (MDR) Acinetobacter baumannii in the hospitals of Europe, North America, Argentina, Brazil, China, Taiwan, Hong Kong, Japan, Korea and even far regions such as Haiti and South Pole (Barbolla et al., 2003; Houang et al., 2001; Levin et al., 1996; Liu et al., 2006; Naas et al., 2005; Nishio et al., 2004) . The diffusion of MDR strains often causes these epidemics at the level of cities, countries and continents (Barbolla et al., 2003; Da Silva et al., 2004; Landman et al., 2002) . It is proved that MDR strains are transferred from regions with high antimicrobial resistance rate to regions with lower rates from Spain to Norway (Onarheim et al., 2000) .
Our results revealed a very high rate of resistance to Cefepim (100%).
In order to evaluate such high rate of resistance, we should consider the mechanisms of drug resistance of Acinetobacter baumannii to Cephalosporins. Although it has been clear that TEM-1 beta-Lactamases occurs in Acinetobacter baumannii, recently, Extended-Spectrum Beta-Lactamases (ESBL) was also noted in Acinetobacter baumannii (Vila et al., 1993) . Strains of Acinetobacter baumannii which carry PER-1 (1 ESBL) show high resistance to Extended-Spectrum Cephalosporins and Penicillins, however fortunately they do not interfere with the resistance of Acinetobacter baumannii to Carbapenems (Perez et al., 2007) . All the samples were resistant to Amikacin which was confirmed by E-test method.Acinetobacter baumannii resistance to Aminoglycosides is mainly attributed to EffluxED ABC pumps and Aminoglycoside changer enzymes. These enzymes include Aminoglycoside Phosphotransferases, Aminoglycoside transferases style, and Aminoglycoside nucleotidyl transferase (Nemec et al., 2004; Vila et al., 1997) .
Current study showed high rate of resistance to Ciprofloxacin too. Actually only 2 samples (4%) showed sensitivity to Ciprofloxacin. In E-test, one sample was identified to be sensitive (50%) and the other one had intermediate sesitivity (50%) to Ciprofloxacin. Resistance of Acinetobacter baumanniito Quinolones is often due to changes in DNA structure of gyrA, which is secondary to mutations in areas that determine resistance to quinolones in gyrA and parC genes (Seward & Towner, 1998; Vila, et al., 1997) . These changes reduce tendency to connect quinolones to DNA-enzyme complex. Another mechanism of resistance to quinolones in created by efflux systems which decreases the aggregation of drug in intercellular spaces (Heinemann et al., 2000) .
Few studies have reported the resistance of Acinetobacte rbaumannii to Colistin, which is a strong warning (Gales et al., 2001; Urban et al., 2001) . Urban et al. (2001) have found a case of Acinetobacter baumannii resistance to Polymyxin B (Urban, et al., 2001) . Mechanism of resistance to Colistin is probably related to changes in Acinetobacter baumannii Lipopolysaccharide (e. g. Acidification, Acylation or the presence of intermediary antigens in connecting antibiotic to cell membrane) (Peterson et al., 1987) . Although in our study the highest rate of Acinetobacter baumannii sensitivity was to Colistin, but out of the 50 samples studied using Disk Diffusion, 8 samples (16%) were resistant to Colistin. However by E-test the resistance pattern was only confirmed in half of them (4 species, 8%)
Resistance rates of Acinetobacter to Carbapenems were as follows: 96% of the samples were resistant to Meropenem and 76% were resistant to Imipenem. Also, 9 isolates had intermediate sensitivity to Imipenem (18%). Acinetobacter baumannii resistance to Carbapenems was significantly related to Beta-lactamases of group B and D. There is Metallo-beta-lactamase in group B, which hydrolyzes Carbapenems and other Beta-lactam antibiotics except in Aztreonam (Walsh, 2005) . On the other hand, in Beta-Lactamases of group D, resistance is secondry to the exsistace of the OXA, which is very alarmingdue to deactivation of Carbapenems. The first description of an OXA Carbapenemase in Acinetobacter baumannii was OXA-23 which was isolated from a clinical sample in Scotland before Carbapenem was discovered (Marqué et al., 2005) .
In the study of Juyal et al. (2013) Inanotherstudy (Shakibaie, et al., 2011) performed on ICUs in Iran, resistance to Imipenem was 73.3% and resistance to Cefepime was 93.3%, which are similar to our findings, while the resistance rates to Ciprofloxacin and Amikacin were 66% and 53.3%, respectively which were much lower than the rate observed in our study.
In a systematic review, antibiotic resistance rate of Acinetobacter baumannii in samples of Iranian patients was evaluated (Moradi et al., 2015) among 3409 samples collecting during 2001 to 2013.The study showed a significant increase in resistance rate against Imipenem and Meropenem, while resistance to lipopeptides and Aminoglycosides did not have a considerable change during these years. Resistance to Carbapenems at the beginning of the research (2001) was low (51.1% for Imipenem and 64.3% for Meropenem) but at the end of the study (2013) it reached 76.5% for Imipenem and 81.5% for Meropenem, showing similar resistance rates to our results. That study also showed that prevalence of MDR Acinetobacter baumannii significantly increased during this period. In this study, resistance to Colistin was between 1.3% to 19% (the latter was similar to our findings).
Comparison of this review to the present study are shown in Table 3 .
Nowadays, effective antibiotics for cure of Acinetobacter baumannii infections include: Aminoglycosides, Fluoroquinolones and Carbapenems (Falagas, et al., 2005) however, because of the high rate of Acinetobacter baumannii resistance to these antibiotics, they cannot be used as empirical treatment. For example, Carbapenems which are commonly prescribed for patients infected with life-threatening Acinetobacter baumannii, have the highest rate of resistance compared to other antibiotics. These facts could explain the reason of therapeutic failures following life-threatening infections with strains resistant to Carbapenem. Recently, Colistin and Tigecycline have emerged as alternative treatment choice for MDR Acintobacter infections. However, resistance to these antimicrobial agents has also been reported as a result of the increased usage of colistin and tigecycline (Capon et al., 2008) .
Although resistance to Colistin is still low, but our study showed increasing resistance to this group which could be problematic in the future. The emergence of resistance has been experienced rapidly after its widespread use (Li et al., 2006; Gounden et al., 2009; Park et al., 2009 ).
Thus, many recent studies have investigated combined therapy of two or more agents for MDR acintobacter infections. Specially combination regimen of Tigecycline or Colistin with other antibiotics have frequently been reported .Park and coworker found a high rate of in vitro synergy and bactericidal activity and lack of antagonism in combination of colistin and Doripenem (Park et al., 2016) . As well as, recent study revealed a superior activity for combination of tigecycline with cefoperazone-sulbactam against MDR acintobacter (Liu et al., 2014) .
Conclusion
Our results clearly showed a very great rate of resistance against most of the antibiotics, usually prescribed for aforementioned infections. There were more than 96% rates of resistance against the antibiotics frequently used in ICU wards (Cefepime, Amikacin, Ciprofloxacin, Imipenemand Meropenem). These results prove that drug resistance, especially against Carbapenem, is increasing fast. Monotherapy should be avoided,because of rapid emerging of resistant, even with Colistin or Tigecycline. Recently combination regimen of the Colistin or Tigecycline with other antibiotics like Cefoprazon-sulbactam or Doripenem are promising in treatment of severe infection specially by MDR acintobacter.
We also hope these results could change the attitude of physicians toward using antibiotics in ICUs and encourage them to follow antibiotic stewardship as the only effective strategy to somewhat control antibiotic resistance in healthcare settings.
